感染影像:聚焦新型示踪剂?
本文综述了心血管感染的分子影像诊断方法,指出[18F]FDG PET与白细胞闪烁显像虽获国际指南认可,但只能反映宿主免疫反应而无法区分感染与炎症;靶向病原体的新型示踪剂是克服此局限的策略,多数尚处临床前阶段,缺乏临床转化。
要点
- [18F]FDG PET与白细胞闪烁显像反映宿主免疫反应,无法区分感染与炎症。
- 靶向病原体的新型分子影像示踪剂是克服上述局限的 promising 策略。
- 多种靶向方案已在临床前评估,但多数仍缺乏临床转化。
核心结论
- 靶向病原体的新型分子影像示踪剂是克服[18F]FDG PET与白细胞闪烁显像无法区分感染与炎症这一局限的 promising 策略。
- 多种靶向方案已在临床前评估,但多数仍缺乏临床转化。
研究设计与样本
- 本文为综述,讨论经临床批准的[18F]FDG PET在心血管感染中的优势与局限,以及基于PET的细菌特异性分子影像新方法。
主要发现
- [18F]FDG PET与白细胞闪烁显像聚焦宿主对病原体的免疫反应,因此实际上无法区分感染与炎症。
- 多种不同的靶向方案已在临床前评估,但多数仍缺乏临床转化。
局限性
- 多数靶向病原体的新型示踪剂仍缺乏临床转化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infections account for relevant morbidity and mortality, especially if the cardiovascular system is affected. Clinical manifestations are often unspecific, resulting in a challenging diagnostic work-up. The use of molecular imaging methods, namely [18F]FDG PET and leukocyte scintigraphy, is increasingly recognized in recently published international guidelines. However, these 2 established methods focus on the host's immune response to the pathogen and are therefore virtually unable to differentiate infection from inflammation. Targeting the microorganism responsible for the infection directly with novel imaging agents is a promising strategy to overcome these limitations. In this review, we discuss clinically approved [18F]FDG PET with its advantages and limitations in cardiovascular infections, followed by new PET-based approaches for the detection of cardiovascular infections by bacteria-specific molecular imaging methods. A multitude of different targeting options has already been preclinically evaluated, but most still lack clinical translation. We give an overview not only on promising tracer candidates for noninvasive molecular imaging of infections but also on issues hampering clinical translation.
引用
- Roll W, Faust A, Hermann S, et al. Infection Imaging: Focus on New Tracers? J Nucl Med. 2023. PMID: 37918846. doi:10.2967/jnumed.122.264869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。